Concerning the incidence of the mentioned side effects, a meta-analysis of large randomized trials with SGLT2 inhibitors showed that these drugs significantly increased the risk of diabetic ketoacidosis (risk ratio-RR 2.57), genital infections (RR 3.75) and volume depletion (RR 1.14); also, there were increased trends observed in the risk of fractures (RR 1.07), lower limb amputations (RR 1.21) and urinary tract infections (RR 1.07) [28]. The gene discussed is SLC5A2; the disease is urinary tract infection.